Laurus Labs Limited

BSE: 540222 NSE: LAURUSLABS
Laurus Labs Limited - pharma in Anakapalle, Andhra Pradesh, India. FY 2026 financials & compliance.
CIN L24239AP2005PLC047518 Incorporated 19 September 2005 ROC Vijayawada HQ Anakapalle, Andhra Pradesh, India
Active Listed - NSE: LAURUSLABS · BSE: 540222 Public Limited Company pharma Fortune India 500 · #418 India's Most Valuable Nifty 500
Data last updated
Market Cap
₹1,28,054 Cr
LAURUSLABS · NSE
Share Price
₹2,454.00
+3.54% today
Revenue
₹6,813 Cr
FY 2025-26 · +22.7% YoY
EBITDA
₹1,778 Cr
Margin 26.1%
Net Profit
₹894 Cr
FY 2025-26 · +216.3% YoY
P/E (TTM)
94.4x
P/B 20.9x
ROE
18.2%
ROCE 16.7%
Debt / Equity
0.54
Interest cover 13.2x

About Laurus Labs Limited

Data last updated:

Laurus Labs Limited is a public limited company based in Anakapalle, Andhra Pradesh, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 19 September 2005 and has been in existence for over 21 years.

Laurus Labs is ranked #418 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director C Satyanarayana is #163 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Vijayawada, under CIN L24239AP2005PLC047518. Its GSTIN is 37AABCL1170C1Z0 (Andhra Pradesh). The company holds 9 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 540222 and NSE: LAURUSLABS.

The company has an authorised share capital of ₹111 Cr and a paid-up capital of ₹108.06 Cr. It was formerly known as Aptuit Laurus Limited and Laurus Labs Private Limited. It is led by directors including Satyanarayana Chava (Whole-Time Director) and Venkata Ravi Kumar Vantaram (Whole-Time Director).

Its last annual general meeting (AGM) was held on 02 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Anakapalle, Andhra Pradesh.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹6,812.9 Cr, a growth of 22.7% compared to the previous year. For the same year it recorded a net profit of ₹894.39 Cr (net margin 13.1%) and EBITDA of ₹1,777.71 Cr (EBITDA margin 26.1%). The net worth stands at ₹5,300.06 Cr (up 18.5% YoY). Total assets are valued at ₹8,642.03 Cr (up 10.5% YoY).

The company has about 5,881 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.

The company is associated with 2 brands: Laurus Labs and Laurus Bio. As per MCA filings, the company has open charges of ₹2,247.77 Cr and satisfied charges of ₹4,204.21 Cr on record. Court records list 45 cases involving the company, including 28 filed by the company and 17 filed against it; 10 cases are pending. The company has 48 deals on record (24 market trades, 13 secondary share transfers, 10 funding rounds), with disclosed funding of ₹518.55 Cr; the latest was in January 2025. Its 3 peer companies in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 1 smaller; the largest is Apitoria Pharma Private Limited with revenue of ₹6,811.62 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lauruslabs.com.

Company details

CIN L24239AP2005PLC047518
Registration Number 047518
Incorporation Date 19 September 2005
ROC Vijayawada
Listing Status Listed - Listed on NSE (LAURUSLABS); Listed on BSE (540222)
Company Status Active
Date of Last AGM 02 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Laurus Labs has undergone 4 name changes throughout its history. The current legal name is Laurus Labs Limited.

Company NameStatus
Laurus Labs LimitedCurrent
Aptuit Laurus LimitedPrevious
Laurus Labs Private LimitedPrevious
Aptuit Laurus Private LimitedPrevious

CIN history

Laurus Labs has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239AP2005PLC047518, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239AP2005PLC047518Current
U24239AP2005PTC047518Previous
U24239AP2005PLC047518Previous
Key People
Satyanarayana Chava Whole-Time Director Venkata Ravi Kumar Vantaram Whole-Time Director Venkata Lakshmana Rao Chunduru Whole-Time Director

Recognitions & Rankings of Laurus Labs

Fortune India 500 2025 edition
Rank#418
Total income
₹5,685 Cr
Profit
₹358 Cr
Last year #411
India's Most Valuable Companies 2025 edition · Source: Hurun India
Valuation
₹59,440 Cr
1-year change
+93%
2024 #197 2023 #218 2022 #167
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Laurus Labs Limited's registered office is in Anakapalle, Andhra Pradesh. Its website is lauruslabs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    lauruslabs.com
  • Social Media
  • Registered Address
    Laurus Enclave Plot Office 01 E. Bonangi Village, Parawada (M) Anakapalli District, Anakapalle, Andhra Pradesh, India – 531021
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Laurus Labs Limited, buy the company report.

Comprehensive company report
Laurus Labs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Laurus Labs operates two associated brands: Laurus Labs and Laurus Bio. Each brand links to its own profile.

BrandDescriptionWebsite
Laurus Labs
Pharmaceutical and biotechnology companylauruslabs.com
Laurus Bio
Precision fermentation services for biopharma and food are provided.laurus.bio

Business activity

The main business activity of Laurus Labs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Laurus Labs Limited, buy the company report.

Financials of Laurus Labs Limited

FY 2025-26 filings available

Laurus Labs Limited reported revenue of ₹6,812.9 Cr (up 22.7% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,813 Cr
+22.7% YoY
EBITDA
₹1,778 Cr
+68.5% YoY
Profit After Tax
₹894 Cr
+216.3% YoY
Net Worth
₹5,300 Cr
+18.5% YoY
Total Assets
₹8,642 Cr
+10.5% YoY
Total Debt
₹2,518 Cr
-8.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Profit before tax1,1824842361,1091,0841,301294
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
Balance sheet
Total assets8,6427,8206,9356,3625,3594,3012,952
Net worth5,3004,4734,1114,0383,3512,5981,770
Total debt2,5182,7642,5772,0151,7771,4821,079
Cash & bank11414414248.4675.9448.461.74
Net working capital2,9892,8492,4402,2461,8041,6441,014
Cash flow
Cash from operations1,624602666994911733347
Cash from investing(1,086)(680)(822)(997)(914)(941)(221)
Cash from financing(525)39.28250(26.64)30.26255(128)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,2062,0261,8121,7781,6531,5701,7201,415
Revenue growth (YoY)+33.4%+29.1%+5.3%+25.7%+35.1%+31.4%--
Other income13.019.1811.805.7626.9610.4358.579.42
EBITDA750638512480403382421285
EBITDA margin+34.0%+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%
Depreciation127124122121120117110106
Interest44.1042.2240.4438.7940.0051.5056.4057.80
Profit before tax592481361327270224312131
Tax15511979.4673.4575.9863.1478.4740.07
Net profit43736228225319416123490.61
EPS (₹)8.166.815.174.653.613.024.331.71
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Profit before tax9945043011,0519751,275304
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
Balance sheet
Total assets7,9057,3086,4325,8965,1784,2552,968
Net worth5,2524,5644,2074,0573,3882,7121,816
Total debt2,0802,3802,1101,7141,6531,4111,051
Cash & bank37.8250.6442.921.7040.5638.780.93
Net working capital2,7332,7632,3482,1861,8441,6991,014
Cash flow
Cash from operations1,385540659882823694345
Cash from investing(847)(592)(757)(735)(837)(900)(217)
Cash from financing(551)59.32139(185)15.19243(127)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0141,7571,5801,5091,5671,4331,6501,265
Revenue growth (YoY)+28.6%+22.6%-4.2%+19.3%+32.2%+28.3%--
Other income24.7220.0713.0914.3728.4521.5272.167.12
Total expenses1,3841,2581,2051,1641,1771,1051,2551,059
EBITDA631499375346390327395206
EBITDA margin+31.3%+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%
Depreciation97.6995.7695.1794.3195.5993.5788.1988.66
Interest38.0235.2033.9131.4833.6843.8948.6048.02
Profit before tax52038825923428921133076.72
Tax13198.2167.5859.3673.1753.5078.3019.45

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,2062,0261,8121,7781,6531,5701,7201,415
Revenue growth (YoY)+33.4%+29.1%+5.3%+25.7%+35.1%+31.4%--
Other income13.019.1811.805.7626.9610.4358.579.42
EBITDA750638512480403382421285
EBITDA margin+34.0%+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%
Depreciation127124122121120117110106
Interest44.1042.2240.4438.7940.0051.5056.4057.80
Profit before tax592481361327270224312131
Tax15511979.4673.4575.9863.1478.4740.07
Net profit43736228225319416123490.61
EPS (₹)8.166.815.174.653.613.024.331.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
Other income54.9575.1026.346.0015.3023.665.92
Total expenses5,0354,4994,2634,4483,5133,2632,267
Employee cost815676615557470397321
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Depreciation480430385324251205187
Interest17121618316510268.1689.59
Profit before tax1,1824842361,1091,0841,301294
Tax29213068.1531225131738.34
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1924,3654,0033,9303,2442,4901,658
Shareholders' funds (net worth)5,3004,4734,1114,0383,3512,5981,770
Minority interest1311304.6211.137.863.150.00
Secured loans1,4251,6741,9281,4251,3731,320875
Unsecured loans1,0931,090649590403161204
Total debt2,5182,7642,5772,0151,7771,4821,079
Total liabilities8,6427,8206,9356,3625,3594,3012,952
Assets
Gross block6,9436,2735,6524,8033,7553,0282,388
Net block4,3714,1233,8903,4092,6522,1711,726
Capital work in progress77345842355181336267.18
Investments30923312449.9030.813.413.41
Inventories2,3421,9371,8451,6851,7601,575905
Sundry debtors2,1552,0071,6631,5801,3541,306791
Cash & bank balances11414414248.4675.9448.461.74
Loans & advances218244185148154145114
Total current assets4,8294,3323,8353,4623,3453,0751,812
Total current liabilities1,8401,4841,3951,2161,5401,431799
Net working capital2,9892,8492,4402,2461,8041,6441,014
Total assets8,6427,8206,9356,3625,3594,3012,952
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash99.5413945.6775.3548.461.692.97
Net cash from operating activities1,624602666994911733347
Net cash from investing activities(1,086)(680)(822)(997)(914)(941)(221)
Net cash from financing activities(525)39.28250(26.64)30.26255(128)
Net change in cash13.12(39.40)93.27(29.68)26.8946.77(1.28)
Closing cash11414414248.4675.9448.461.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
EBITDA growth+68.5%+35.7%-51.2%+11.9%-8.3%+174.7%-
PBT growth+144.0%+104.9%-78.7%+2.3%-16.7%+343.1%+145.2%
Net income growth+216.3%+74.9%-79.5%-4.6%-15.8%+284.6%-
Revenue CAGR (3Y)+4.1%+4.0%+1.6%+28.7%+29.1%+32.8%+14.1%
EBITDA CAGR (3Y)+3.7%-9.5%-20.6%+41.3%+58.7%+55.4%+11.5%
Profitability & leverage
Net income margin+13.1%+6.4%+3.3%+13.2%+16.9%+20.4%+9.0%
Return on capital employed+16.7%+8.8%+6.3%+21.8%+24.6%+37.8%+13.6%
Return on net worth+18.2%+6.5%+4.1%+21.6%+28.0%+45.1%+15.3%
Debt / equity0.540.620.560.510.550.590.64
Long-term debt / equity0.150.180.200.190.180.150.13
Interest cover13.1634.5546.5513.028.745.0723.75
Efficiency & per share
Fixed asset turnover1.030.930.961.411.461.781.26
Inventory turnover3.182.942.863.512.963.883.57
Debtors turnover3.273.033.114.123.714.593.77
EPS (₹)16.466.642.9814.6715.4018.3323.88
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)98.1882.9476.2874.9662.3748.41165.11
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0141,7571,5801,5091,5671,4331,6501,265
Revenue growth (YoY)+28.6%+22.6%-4.2%+19.3%+32.2%+28.3%--
Other income24.7220.0713.0914.3728.4521.5272.167.12
Total expenses1,3841,2581,2051,1641,1771,1051,2551,059
EBITDA631499375346390327395206
EBITDA margin+31.3%+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%
Depreciation97.6995.7695.1794.3195.5993.5788.1988.66
Interest38.0235.2033.9131.4833.6843.8948.6048.02
Profit before tax52038825923428921133076.72
Tax13198.2167.5859.3673.1753.5078.3019.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
Other income77.4310047.4215.9521.5527.325.81
Total expenses4,6514,2734,0634,2923,4223,2592,227
Employee cost684571532478418365300
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Depreciation379359345301235197184
Interest14318215114695.8665.9287.71
Profit before tax9945043011,0519751,275304
Tax25412377.7729122531937.43
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1444,4564,0993,9493,2812,6051,709
Shareholders' funds (net worth)5,2524,5644,2074,0573,3882,7121,816
Secured loans1,0301,3251,4801,1341,2611,257847
Unsecured loans1,0501,054630580392155204
Total debt2,0802,3802,1101,7141,6531,4111,051
Total liabilities7,9057,3086,4325,8965,1784,2552,968
Assets
Gross block5,3654,8794,7064,2223,2542,6572,341
Net block3,0412,8883,0362,8842,1861,8181,694
Capital work in progress56933615635775532466.53
Investments89174063538436231958.32
Inventories2,1361,7391,6971,5691,6891,534893
Sundry debtors2,0232,0351,6401,4871,2691,280778
Cash & bank balances37.8250.6442.921.7040.5638.780.93
Loans & advances165182137113206189112
Total current assets4,3634,0073,5173,1713,2053,0411,785
Total current liabilities1,6301,2431,1709861,3601,343771
Net working capital2,7332,7632,3482,1861,8441,6991,014
Total assets7,9057,3086,4325,8965,1784,2552,968
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash50.3642.631.4240.3338.780.880.51
Net cash from operating activities1,385540659882823694345
Net cash from investing activities(847)(592)(757)(735)(837)(900)(217)
Net cash from financing activities(551)59.32139(185)15.19243(127)
Net change in cash(12.85)7.7341.21(38.91)1.5537.900.37
Closing cash37.8250.6442.921.7040.5638.780.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
EBITDA growth+52.3%+25.9%-49.4%+15.3%-14.9%+164.8%-
PBT growth+97.3%+67.1%-71.3%+7.8%-23.5%+318.6%+151.2%
Net income growth+144.2%+35.8%-70.5%+1.3%-21.5%+257.4%-
Revenue CAGR (3Y)+1.8%+3.5%+0.3%+27.3%+28.2%+33.0%+13.9%
EBITDA CAGR (3Y)-1.0%-9.8%-20.8%+37.5%+54.1%+54.6%+11.3%
Profitability & leverage
Net income margin+12.2%+7.3%+4.7%+13.2%+15.9%+20.1%+9.6%
Return on capital employed+15.0%+9.1%+7.3%+21.6%+22.7%+37.1%+13.9%
Return on net worth+15.1%+6.9%+5.4%+20.4%+24.6%+42.2%+15.7%
Debt / equity0.450.510.460.450.500.540.60
Long-term debt / equity0.090.110.140.160.160.130.13
Interest cover13.4931.1237.2512.349.135.0222.70
Efficiency & per share
Fixed asset turnover1.191.091.081.541.591.911.27
Inventory turnover3.143.042.953.542.923.933.59
Debtors turnover3.002.843.084.193.694.633.82
EPS (₹)13.727.054.1514.1213.9617.8224.98
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)97.2984.6478.0675.3163.0550.54169.84

To see the full year-wise statements and ratios of Laurus Labs Limited, buy the company report.

Board of directors of Laurus Labs Limited

Laurus Labs has 10 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Satyanarayana Chava
Also directs: Immunoadoptive Cell Therapy Private Limited, Laurus Bio Private Limited, Krka Pharma Private Limited and 1 more
Whole-Time Director21 Jan 200620 Years 9 MonthsCurrent
Venkata Ravi Kumar Vantaram
Also directs: Laurus Bio Private Limited, Krka Pharma Private Limited, Taram Estates LLP
Whole-Time Director30 Nov 200619 Years 11 MonthsCurrent
Venkata Lakshmana Rao Chunduru
Also directs: Sriam Labs Private Limited
Whole-Time Director08 Mar 20188 Years 8 MonthsCurrent
Ravindranath Kancherla
Also directs: Hygieia Global Health Services LLP, Arunachalam Automotives Private Limited, Cognitivebotics Technologies Private Limited and 5 more
Director18 May 20179 Years 5 MonthsCurrent
Ramesh Subrahmanian
Also directs: Integris Medtech Limited
Director25 Jul 20242 Years 3 MonthsCurrent
Sekar Karnam
Also directs: Laurus Bio Private Limited, Ugro Capital Limited, Incred Financial Services Limited and 1 more
Director25 Apr 20242 Years 6 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Laurus Labs Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Laurus Labs Limitedthis company₹6,812.9 Cr (FY 2026)₹894.39 Cr13.1%22.7%5,881Anakapalle, Andhra Pradesh, India
Apitoria Pharma Private Limited₹6,811.62 Cr (FY 2025)20.0%Hyderabad, Telangana, India
MSN Laboratories Private Limited₹6,761.18 Cr (FY 2024)27.0%Hyderabad, Telangana, India
Cadila Pharmaceuticals Limited₹3,869.17 Cr (FY 2025)4.0%Ahmedabad, Gujarat, India

To see the full peer comparison of Laurus Labs Limited, buy the company report.

Auditor

Laurus Labs Limited is audited by Deloitte Haskins & Sells Llp for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & Sells LlpFY 2024117366W/W-100018

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 27.50%, foreign institutional investors hold 28.00%, domestic institutional investors hold 13.70% and retail and other public shareholders hold 30.80%.

Promoters: 27.50%DII (Domestic Institutional): 13.70%FII (Foreign Institutional): 28.00%Retail & Others: 30.80%
Sep 2026
QUARTER
27.50% Promoters
13.70% DII (Domestic Institutional)
28.00% FII (Foreign Institutional)
30.80% Retail & Others
Promoter holding - history
Now 27.50% · Sep 2026High 27.60% · Dec 2025Low 27.50% · Mar 2026
26%26.8%27.5%28.3%29%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 27.60%Mar 2026: 27.50%Jun 2026: 27.50%Sep 2026: 27.50%27.60%27.50%27.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters27.50%27.50%27.50%27.60%
Public72.50%72.50%72.50%72.40%

Charges & borrowings

Open charges
₹2,247.77 Cr
Satisfied charges
₹4,204.21 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹1,589.77 Cr
Others₹508.00 Cr
Jp Morgan Chase Bank, N.A.₹150.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
01 Oct 2026101399259Others₹250 CrOpen
07 Aug 2026101363701Jp Morgan Chase Bank, N.A.₹150 CrOpen
29 Aug 2024100969026Others₹258 CrOpen
16 May 2022100574403Sbicap Trustee Company Limited₹1,589.77 CrOpen
18 Feb 2026101238887Others₹200 CrSatisfied

To see the full charge records of Laurus Labs Limited, buy the company report.

Total charge records: 40 View all charges

Deals & funding

Laurus Labs Limited has 48 deals on record (24 market trades, 13 secondary share transfers, 10 funding rounds), with disclosed funding of ₹518.55 Cr; the latest was in January 2025.

Total deals
48
Market trades
24
Secondary share transfers
13
Funding rounds
10
IPO
1
Disclosed funding
₹518.55 Cr

Deals on record (5 of 48)

WhenDealAmountParties
Jan 2025Market trade₹198.01 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Oct 2024Funding round₹10 CrInvestors: Elpro International Limited
Mar 2023Market trade₹19.4 CrBuyer: an individual
Seller: Cybage Software Private Limited
Aug 2020Market trade₹65.1 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jun 2020Market trade₹667.23 CrBuyer: Setu Securities Private Limited , Government Pension Fund Global, 2 individuals
Seller: Bluewater Investment Ltd, Setu Securities Private Limited , Millennium Stock Broking Private Limited , an individual

To see the full deal history of Laurus Labs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Laurus Labs Limited was last rated by Care on 24 Jun 2021.

Rating agencyRated onRating
Care24 Jun 2021

To see the full credit ratings and regulatory alerts of Laurus Labs Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Laurus Labs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Laurus Labs has 4 subsidiary companies and 2 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

4
Subsidiary companies
2
Associated companies
Key subsidiaries
Company NameCINShares held
Laurus Bio Private LimitedU02423KA2005PTC036770
Laurus Synthesis Private LimitedU24110TG2020PTC140333
Laurus Specialty Chemicals Private LimitedU24110TG2022PTC168791
Sriam Labs Private LimitedU24239TG2002PTC038490

To see the full group structure of Laurus Labs Limited, buy the company report.

Employees & EPFO

Laurus Labs Limited has a workforce of 5,881 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.

Employee count
5,881
Active EPFO establishments
1
Employee growth
4.55%

GST

Laurus Labs has 9 GST registrations: 5 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
9
Active
5
Cancelled / inactive
4
GSTINStateStatusRegistered on
37AABCL1170C1Z0Andhra PradeshActive01 Jul 2017
37AABCL1170C2ZZAndhra PradeshActive06 Jul 2017
37AABCL1170C3ZYAndhra PradeshActive11 Jul 2017
36AABCL1170C1Z2TelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Laurus Labs Limited, buy the company report.

Recent activity

Laurus Labs Limited has 49 board changes on record since 2005: 30 appointments and 19 cessations. The latest: Shekhar Chintamani Mande was appointed as Director on 02 Jul 2026.

Charges
A charge with Others amounted to Rs. 250.00 Cr with Charge ID 101399259 was registered on 01 Oct 2026.
Charges
A charge registered on 18 Feb 2026 via Charge ID 101238887 with Others was fully satisfied on 04 Sep 2026.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 1,589.77 Cr registered on 16 May 2022 with Charge ID 100574403 was modified on 17 Aug 2026.
Charges
A charge with Jp Morgan Chase Bank, N.A. amounted to Rs. 150.00 Cr with Charge ID 101363701 was registered on 07 Aug 2026.
AGM
Laurus Labs Limited last Annual general meeting of members was held on 02 Jul 2026 as per latest MCA records.
Appointed
Shekhar Chintamani Mande was appointed as Director.
Appointed
Sutapa Banerjee was appointed as Director.
Filing
Laurus Labs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Vijayawada.
Charges
A charge with Others amounted to Rs. 200.00 Cr with Charge ID 101238887 was registered on 18 Feb 2026.
Charges
A charge registered on 21 Mar 2025 via Charge ID 101064181 with Others was fully satisfied on 17 Feb 2026.
Charges
A charge with Others amounted to Rs. 200.00 Cr with Charge ID 101064181 was registered on 21 Mar 2025.
Charges
A charge registered on 14 Mar 2023 via Charge ID 100698296 with Axis Bank Limited was fully satisfied on 07 Nov 2024.

133 earlier events are in the company report.

News

LAURUSLABS: Q2 CONS NET PROFIT 4.4B RUPEES VS 1.95B (YOY); EST 3.54B
29 Oct 2026 · Exchange Update
LAURUSLABS: Q2 EBITDA 7.5B RUPEES VS 4B (YOY), EST 6.44B; Q2 EBITDA MARGIN 34% VS 24.39% (YOY), EST 30.5%
29 Oct 2026 · Exchange Update
Laurus Labs: Co Reports That LB-4 Fermentation Manufacturing Unit Is Advancing On Schedule (>400KL) And Will Be Ready By Q3 FY27.
29 Oct 2026 · Exchange Update
Laurus Labs: Invests ₹1,078 Crore In Krka Pharma Through Rights Issue To Acquire 107.8 Million Shares.
14 Oct 2026 · Exchange Update
LAURUSLABS: RS. 61.44 CRORES BSE BLOCK TRADE; FOR ~ 302,000 SHARES, AT RS. 2034.30
08 Oct 2026 · Exchange Update

Frequently asked questions

Laurus Labs is an active public limited company based in Anakapalle, Andhra Pradesh, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 19 September 2005 (21+ years old) and is registered under CIN L24239AP2005PLC047518. Listed on BSE: 540222 and NSE: LAURUSLABS.

Laurus Labs reported revenue of ₹6,812.9 Cr for FY 2025-26 (up 22.7% YoY) based on consolidated financials.

Laurus Labs has 10 current directors:

The latest financial statements of Laurus Labs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 02 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Laurus Labs is 37AABCL1170C1Z0, registered in Andhra Pradesh. The company has 9 GST registrations in all, of which 5 are active and 4 are cancelled or inactive. Other active GSTINs include 37AABCL1170C2ZZ (Andhra Pradesh), 37AABCL1170C3ZY (Andhra Pradesh), 36AABCL1170C1Z2 (Telangana).

The CIN (Corporate Identification Number) of Laurus Labs is L24239AP2005PLC047518. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Laurus Labs is a listed company as per MCA records. Its shares are listed on both BSE (code: 540222) and NSE (symbol: LAURUSLABS).

Laurus Labs has 45 court cases on record: 28 filed by the company and 17 filed against it. 10 are pending. Most are in the high courts.

Laurus Labs was incorporated on 19 September 2005, making it 21+ years old. It is registered with the Registrar of Companies, Vijayawada.

Laurus Labs has 48 deals on record (24 market trades, 13 secondary share transfers, 10 funding rounds), with disclosed funding of ₹518.55 Cr; the latest was in January 2025.

The peers of Laurus Labs by revenue are Apitoria Pharma Private Limited, MSN Laboratories Private Limited, Cadila Pharmaceuticals Limited, all in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).